Skip to main content

Bioconjugation services

CheMatech provides tailored bioconjugation services for the design and preparation of targeted conjugates for nuclear medicine applications. Leveraging our broad portfolio of chelators and functionalized building blocks, we support the development of bioconjugates optimized for stability, targeting efficiency, and in vivo performance.

Selecting the appropriate chelator is critical to ensure high complex stability, preserve the biological activity of the targeting vector, and minimize radionuclide release in vivo. Our team supports you in identifying the most suitable chelation and conjugation strategy based on your radionuclide, vector, and intended application.

We offer bioconjugation solutions for a wide range of biomolecules (mAbs, Fab, nanobodies, VHHs, etc.), using chemistries adapted to:

  • Cysteine residues
  • Lysine residues
  • Click chemistry approaches

Both the chelator and the conjugation strategy can be tailored to your specific requirements, enabling the development of optimized conjugates aligned with your project objectives.

cGMP Bioconjugation for Clinical Development

As a specialized CDMO partner, CheMatech offers cGMP-compliant bioconjugation services to support the transition from preclinical development to clinical trials.

Our integrated capabilities enable process development, scale-up, and manufacturing of bioconjugates in a controlled cGMP environment, ensuring full compliance with regulatory expectations. We place strong emphasis on process robustness, reproducibility, and analytical control to deliver conjugates suitable for clinical use.

Through our expertise in chelators and radiopharmaceutical chemistry, we support our partners in accelerating the development of safe, reliable, and scalable conjugation processes for clinical applications.